Main Article Content
Abstract
Keywords
Article Details
References
- deBoer RA and van Veldhuisen DJ (2008). ACE-inhibitors, Beta-blockers or the combination in heart failure: is it just an A-B-C?. Cardiovasc Drugs Ther 22, 261–263
- Januzzi JL, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim HN, Baggish AL, Weiner RB, Chen-Tournoux A, Marshall JE (2011). Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. Journal of the American College of Cardiology 58, 1881-1889
- Kim HN and Januzzi JL (2011). Natriuretic peptide testing in heart failure. Circulation 123, 2015-2019
- Loscalzo J (2010). Harrison’s: Cardiovascular Medicine, New York, McGraw-Hill Comp, p 178-197
- Morrow DA (2006). Cardiovascular Biomarkers: Pathophysiology And Disease Management, New Jersey, Humana Press Inc, p 345-370
- Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M (2004). Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med 42, 942-944
- Savioli NF, Magalhães HM, Batlouni M, Piegas LS (2009). ACE inhibitors and plasma B-type natriuretic peptide levels in elderly patients with heart failure. Arquivos Brasileiros de Cardiologia 92, 349-356
- Srisawasdi P, Vanavanan S, Charoenpanichkit C, Kroll MH (2010). The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. American Journal of Clinical Pathology 133, 14-23
- Tsutamoto T, Sakai H, Ishikawa C, Fujii M, Tanaka T, Yamamoto T, Takashima H, Ohnishi M, Wada A, Horie M (2007). Direct comparison of transcardiac difference between brain natriuretic peptide (BNP) and N-terminal pro-BNP in patients with chronic heart failure. European Journal of Heart Failure 9, 667-673
- Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T, Kinoshita M (2001). Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. Journal of the American College of Cardiology 37, 1228–1233
- Tsutamoto T, Wada A, Sakai H, Ishikawa C, Tanaka T, Hayashi M, Fujii M, Yamamoto T, Dohke T, Ohnishi M, Takashima H, Kinoshita M, Horie M (2006). Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. Journal of the American College of Cardiology 47, 582-586
References
deBoer RA and van Veldhuisen DJ (2008). ACE-inhibitors, Beta-blockers or the combination in heart failure: is it just an A-B-C?. Cardiovasc Drugs Ther 22, 261–263
Januzzi JL, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim HN, Baggish AL, Weiner RB, Chen-Tournoux A, Marshall JE (2011). Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. Journal of the American College of Cardiology 58, 1881-1889
Kim HN and Januzzi JL (2011). Natriuretic peptide testing in heart failure. Circulation 123, 2015-2019
Loscalzo J (2010). Harrison’s: Cardiovascular Medicine, New York, McGraw-Hill Comp, p 178-197
Morrow DA (2006). Cardiovascular Biomarkers: Pathophysiology And Disease Management, New Jersey, Humana Press Inc, p 345-370
Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M (2004). Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med 42, 942-944
Savioli NF, Magalhães HM, Batlouni M, Piegas LS (2009). ACE inhibitors and plasma B-type natriuretic peptide levels in elderly patients with heart failure. Arquivos Brasileiros de Cardiologia 92, 349-356
Srisawasdi P, Vanavanan S, Charoenpanichkit C, Kroll MH (2010). The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. American Journal of Clinical Pathology 133, 14-23
Tsutamoto T, Sakai H, Ishikawa C, Fujii M, Tanaka T, Yamamoto T, Takashima H, Ohnishi M, Wada A, Horie M (2007). Direct comparison of transcardiac difference between brain natriuretic peptide (BNP) and N-terminal pro-BNP in patients with chronic heart failure. European Journal of Heart Failure 9, 667-673
Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T, Kinoshita M (2001). Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. Journal of the American College of Cardiology 37, 1228–1233
Tsutamoto T, Wada A, Sakai H, Ishikawa C, Tanaka T, Hayashi M, Fujii M, Yamamoto T, Dohke T, Ohnishi M, Takashima H, Kinoshita M, Horie M (2006). Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. Journal of the American College of Cardiology 47, 582-586